Description
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Principal Investigator
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS